Table 3.
Variation in reported incidence of L265P mutation based on assay methodology [adapted from Treon and Hunter (12)]
| Method1 | Source1 | WM | IgM MGUS | Reference |
|---|---|---|---|---|
| Sanger sequencing | BM CD19+ | 91% | 10% | Treon, 2012 (12) |
| Sanger sequencing | BM | - | 54% | Landgren, 2012 (25) |
| Sanger sequencing | - | 70% | - | Ansell, 2012 (26) |
| PCR | BM | 67% | - | Gachard, 2013 (27) |
| PCR | BM | 79% | - | Poulain, 2013 (28) |
| Allele-specific PCR | BM/Lymph Nodes | 86% | 87% | Jimenez, 2013 (29) |
| Allele-specific PCR | BM | 72% | - | Mori, 2013 (30) |
| Allele-specific PCR | BM/PBMC | 100% | 47% | Varettoni, 2013 (31) |
| Allele-specific PCR | BM CD19+ | 93% | 54% | Xu, 2013 (32) |
1
BM, Bone Marrow; PCR, Polymerase Chain Reaction